Articles tagged with Influenza Viruses
Researchers at Northwestern University have found that the influenza virus reduces immune system-regulating protein production in human cells by activating specific microRNAs. This discovery sheds light on a new mechanism of viral immune evasion and may lead to the development of therapeutics to preserve the immune response.
Researchers found that a prime-boost vaccine regimen can elicit broadly neutralizing antibodies in animals with pre-existing immunity, offering hope for developing vaccines giving long-lasting flu protection. The study's results suggest that a universal flu vaccine may be possible, potentially benefiting people of all ages.
Researchers at Scripps Research Institute describe three human antibodies protecting against a wide variety of flu viruses, including Influenza B strains. These broadly neutralizing antibodies may provide key clues to designing an active universal flu vaccine.
A new strain of influenza virus found in harbor seals has adaptations to living in mammals and may pose a threat to human health. The virus's ability to target a receptor found in the human respiratory tract raises concerns about its potential to cause severe disease.
Researchers developed mathematical models to investigate viral control factors, revealing that innate immune responses, such as natural killer cells and interferon, explain the initial rapid decline and subsequent second peak of viral levels. Ultimately, the adaptive immune response is necessary for eventual viral clearance.
Researchers from the University of Cambridge found that avian H5N1 influenza viruses could potentially acquire mutations necessary for airborne transmission in nature. The study suggests that with as few as five mutations, or four mutations plus reassortment, these viruses can become airborne transmissible between mammals and humans.
Research found microneedle vaccine patches are more effective than traditional inoculation methods against influenza virus in mice. The patches trigger a local increase of cytokines and activate dendritic cells, leading to a strong innate immune response.
A meta-analysis of 159 studies found rapid influenza diagnostic tests (RIDTs) can confirm the flu, but not rule it out; RIDTs are more accurate in children than adults and better at detecting influenza A virus; this suggests routine implementation of RIDTs during flu season could improve patient care.
A randomized controlled trial found that vaccinating pregnant women against influenza increased mean birth weight and reduced small-for-gestational-age births. The study, conducted in Bangladesh, involved 340 healthy pregnant women who received either the influenza vaccine or a control vaccine.
Scientists have identified peptides on internal structures of influenza viruses that could provide immunity against all strains, including seasonal and pandemic flu. This breakthrough could lead to the development of a universal vaccine that activates T-cell immune responses.
A new diagnosis technique has been developed to detect influenza virus infection in just 40 minutes, surpassing conventional methods in speed and sensitivity. This technique was confirmed through clinical research conducted in Japan during the 2009 pandemic, demonstrating its effectiveness in rapidly identifying infected patients.
Scientists at the International Vaccine Institute have discovered a sublingual vaccine that protects mice against various flu viruses, including H5 and H1. The vaccine induces immunity in the lungs and offers an alternative strategy to prevent influenza infection.
Flu strains migrate globally, evolving along the way, contradicting the theory that they come from tropical areas. Influenza viruses in tropical regions show relatively low levels of genetic diversity and no seasonal fluctuations.
Researchers found that influenza viruses can circulate globally, with multiple urban centers acting as sources of seasonal epidemics. The study used RNA sequences from 2003-2006 and showed high rates of viral migration among cities, challenging the long-held theory that tropical areas are the only source of seasonal flu.
Researchers discovered proteins and genetic material from the 1918 influenza virus in specimens from 37 soldiers, including four who died between May and August 1918. The findings suggest that the virus did not undergo a dramatic change during the pandemic, contributing to unusually high mortality.
Researchers have determined the three-dimensional structure of a complex between an influenza B virus protein and its human protein target, resulting in suppression of the cell's natural defenses. This discovery could lead to the development of antiviral drugs against influenza B virus.
Researchers at Humabs BioMed SA have discovered the first antibody to target all 16 hemagglutinin subtypes of influenza A, representing a promising treatment option for severe cases of flu. The novel monoclonal antibody, FI6, has been shown to protect mice and ferrets from infection by influenza A virus using multiple mechanisms.
Researchers used computational techniques to analyze 5,000 strains of influenza A viruses and identified six strains with particularly close genetic relationships to the H1N1 pandemic virus. These 'bottleneck' viruses were found to be the culprits behind the emergence of the pandemic strain.
InDevR received a $3 million Phase II NIH grant to develop an integrated molecular diagnostic platform for influenza screening. The technology aims to provide accurate, rapid, and cost-effective identification of influenza viruses.
A new study has successfully trialed a synthetic universal flu vaccine in mice, providing 100% protection against the H3N2 strain and 20% against the highly pathogenic bird flu. The vaccine uses peptides that trigger an immune response to a region of the flu virus present in all influenza A and B viruses.
A study by Virginia Tech researchers found that airborne influenza A viruses can remain suspended in the air for hours and are associated with fine particles less than 2.5 micrometers. The average concentration of viruses was 16,000 per cubic meter of air, which is sufficient to induce infection.
Researchers at Scripps Research Institute found that enzyme ADAR1 slows down measles virus replication and protects cells against other respiratory viruses. The discovery provides a significant improvement in understanding measles infections, which kill around 150,000 children and adults worldwide.
A new study in BioEssays reveals that the H1N1 pandemic challenged the conventional ideal of antigenic shift, where a virus emerges from an existing subtype. The research suggests that pandemics can result from a shift within lineages of existing subtypes, not just the introduction of a new strain.
A study published in PLoS ONE found that iota-carrageenan directly binds to influenza viruses, blocking attachment and spread. In animal experiments, it demonstrated equivalent efficacy to Tamiflu, offering a potential alternative for treating H1N1 influenza.
A new computer model projects flu season severity by analyzing genetic and serological data, explaining over 90% of variation in severity. The study provides insights for informed decision-making in planning for influenza, including vaccine selection.
A recent study found that inactivated flu vaccines are effective in preventing influenza in infants under 2 years old. The research suggests that most countries' current vaccination guidelines should be reassessed to prioritize infant protection against the virus.
The article discusses ongoing research to improve influenza vaccines, including the development of novel production technologies and approaches such as recombinant virus proteins and universal flu vaccines. These efforts aim to provide better protection against multiple strains of influenza and novel flu viruses in the future.
Scientists from Brigham Young University and Florida State University have made a breakthrough in understanding the flu virus's structure, identifying a potential drug target. By mapping the M2 channel's atomic level details, researchers can now develop new treatments that can defeat the virus regardless of its mutations.
A study found that maternal influenza vaccination during pregnancy is associated with lower rates of flu infection and hospitalization in infants. Infants born to vaccinated mothers had higher levels of flu antibodies, providing protection against severe illness.
Researchers developed a prime-boost vaccine strategy that generated antibodies capable of neutralizing multiple flu strains, including those from different years and subtypes. The vaccine showed significant promise in animal models, with up to 80% survival rate after exposure to high levels of flu virus.
Researchers at University of Miami use computer algorithms to design live vaccines, which are then synthesized to specification. This approach allows for a wide margin of safety against potential mutations, enabling the creation of safe and effective vaccines against various types of viruses.
Researchers at Mount Sinai School of Medicine have discovered a novel component of the influenza virus that may be the key to developing a universal anti-viral treatment. By inhibiting this component, replication and spread of the virus can be slowed or halted.
A Singaporean study analyzed trends and symptoms among patients during the 2009 pandemic, finding that pandemic influenza was milder than seasonal flu, with fewer cases of fever and upset stomach. The study also found that pandemic influenza affected younger individuals more often than older adults.
Researchers have developed a novel influenza vaccine that could represent the next step towards a universal influenza vaccine eliminating seasonal immunizations. The vaccine uses headless hemaglutinin (HA) protein, inducing a broader and more robust immune response in mice.
A study by the University of Washington found that Google Flu Trends is less accurate in estimating laboratory-confirmed influenza cases compared to CDC surveillance. The analysis revealed a 25% error margin during the 2003-04 flu season, with greatest deviations occurring during periods of high media attention or unexpected activity.
Scientists from Freiburg and Berlin have unraveled the secret of the Mx protein, which plays a crucial role in inhibiting influenza virus replication. The Mx protein forms a ring-structured macromolecular network that restrains and deactivates viral components, providing a defense mechanism against new flu viruses.
Chronic stress accelerates tumor growth in ovarian cancer patients by protecting cells from anoikis, a process that allows tumor cells to survive and grow. Stress hormones norepinephrine and epinephrine activate the protein FAK, leading to accelerated mortality.
Researchers found that individuals vaccinated with seasonal influenza vaccine produce antibodies targeting H5 HA, protecting mice from pandemic H1N1 and several H5N1 viruses. However, more work is needed to determine antibody levels and vaccination effectiveness against different influenza virus subtypes.
Research suggests that including both strains of influenza B in the seasonal flu vaccine could improve its effectiveness in preventing the disease. Studies found that vaccines containing only one strain of influenza B were less effective in protecting against the flu, particularly in children.
Researchers have discovered an influenza detector gene called RIG-I in ducks that could prevent the transmission of the virus to humans. The duck's immune system contains the virus, reducing viral replication by half.
Researchers found that pandemic influenza viruses from 1918 and 2009 share a structural detail that makes them susceptible to neutralization by the same antibodies. Vaccination with either virus can generate cross-reactive antibodies capable of neutralizing the other virus.
The Scripps Research Institute team solved the structure of the 'swine flu' virus, revealing similarities with earlier human flu viruses. This discovery helps explain why older individuals were less severely affected by the recent outbreak than younger ones.
Researchers found that CS-8958 resulted in higher survival rates and lower virus levels than oseltamivir in mouse models. The novel compound also protected mice from lethal H5N1 infection when given before or after exposure to the virus.
A new study published in PLoS Biology found that absolute humidity is the underlying cause of seasonal influenza outbreaks. The researchers used 31 years of observed data to drive a mathematical model of influenza and found that the model simulations reproduced the observed seasonal cycle of influenza throughout the United States.
A new study found that genetic interactions between avian H5N1 influenza and human seasonal influenza viruses can create hybrid strains with increased virulence. The researchers identified a key gene segment, PB2, which is responsible for the increased pathogenicity.
Research reveals that flu-induced stress response is critical for resistance to secondary infection, involving increased production of glucocorticoids to control inflammation. The study found that mice without GCs were better able to suppress secondary bacterial infections, but lacking GCs led to a lethal excessive inflammatory response.
The pandemic H1N1 influenza virus replicates efficiently in lung cells and infects conjunctiva, suggesting a potential route of transmission; however, it does not induce cytokine dysregulation like highly pathogenic avian flu viruses.
The BC Centre for Disease Control has launched a genomic surveillance project to study the evolution of the pandemic H1N1 flu virus in British Columbia. Researchers will compare the genetic sequences of BC's influenza viruses with those from other regions to understand how mass gatherings like the Olympics impact the virus' evolution.
Researchers at Medical College of Wisconsin develop rapid semi- and fully-automated multiplex real-time RT-PCR assays for detecting human H1N1, H3N2, and swine-origin H1N1 viruses. The tests can distinguish between influenza A, B, and RSV infections, reducing technician and assay time.
A new compound, T-705, has been found to be effective and safe against H5N1 virus, a highly pathogenic bird flu virus, even three days after infection. The compound works by targeting the viral polymerase enzyme, making it a promising front-line drug for treating influenza.
A team of researchers has identified a human protein called IFITM3 that blocks the replication of H1N1 influenza virus and other viruses. The discovery could lead to the development of more effective antiviral drugs, including prophylactic drugs to slow influenza transmission.
Researchers at Berkeley Lab have identified a new genetic mutation in the H1N1 flu virus that enables it to replicate in humans. The SR polymorphism mutation enhances polymerase activity and potentially pathogenesis of the virus in humans.
Autopsies show that the 2009 H1N1 virus causes damage to both upper and lower respiratory tracts, with evidence of secondary bacterial infection present in over half of victims. The study also highlights the impact on younger people and the importance of identifying and treating severe infections.
The study estimates that vaccination, social distancing and antivirals can blunt the impact of H1N1 influenza. The median incubation period was 4 days and symptoms lasted 7 days.
A new study found that healthy adults have a level of protective immune memory against the 2009 H1N1 influenza virus. This immunity can blunt the severity of infection and provide some protection. The findings may explain why younger children are more severely affected by the pandemic.
MedImmune to present four abstracts on respiratory syncytial virus (RSV) and influenza prevention at the 47th Annual IDSA Meeting. The studies highlight innovative healthcare solutions for respiratory infections in children. Abstracts focus on prophylaxis, postmarketing evaluation, whole genome transcriptional analysis, and antibiotic use
A new study reveals a relationship between the evolution of the influenza virus and immunization rates needed to prevent outbreaks. The research team found that the degree of variability in population immunity plays a crucial role in determining the risk of an outbreak.
Researchers found that high-affinity mutant viruses alternate with low-affinity forms in antigenic drift. Increasing child vaccination could slow this process and extend seasonal influenza vaccine effectiveness.
The PLOS collection explores how genomics can provide insights into emerging infectious diseases. Genomics research has the potential to track the spread of disease agents, develop vaccines, and combat pathogens more effectively. This could lead to a better preparedness for and response to biological threats.
A recent large-scale swine flu outbreak at the US Air Force Academy provided valuable insights into the natural behavior of the nH1N1 virus, including shedding patterns. The study found that viable virus shedding occurred in about one quarter of confirmed patients and persisted even after symptom-free periods.